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Sclerosis: a randomised controlled trial (CRAMMS) 
 
Abstract 
 
Objective 
To assess the clinical and cost-effectiveness of cognitive rehabilitation for attention 
and memory problems in people with multiple sclerosis 
Design 
Multi-centre, pragmatic, randomised controlled trial 
Setting 
Community 
Participants 
People with multiple sclerosis aged 18 to 69 years, who reported cognitive problems 
in daily life and had cognitive problems on standardised assessment. 
Interventions 
A group cognitive rehabilitation programme delivered in 10 weekly sessions in 
comparison with usual care 
Main measures 
The primary outcome was the Multiple Sclerosis Impact Scale Psychological 
subscale at 12 months after randomisation. Secondary outcomes included measures 
of everyday memory problems, mood, fatigue, cognitive abilities and employment at 
6 and 12 months after randomisation. 
 
 Results 
245 participants were allocated to cognitive rehabilitation and 204 to usual care. 
Mean Multiple Sclerosis Impact Scale Psychological at 12 months was 22.2 [SD=6.1] 
for cognitive rehabilitation and 23.4 [SD=6.0] for usual care group; adjusted 
difference -0.6, 95% CI -1.5 to 0.3, p=0.20.  No differences were observed in 
cognitive abilities, fatigue or employment.  There were small differences in favour of 
cognitive rehabilitation for the Multiple Sclerosis Impact Scale Psychological at 6 
months and everyday memory and mood at 6 and 12 months. There was no 
evidence of an effect on costs (-£808 95% CI -£2248 to £632) or on quality adjusted 
life year gain (0.00 95% CI -0.01 to 0.02). 
 
Conclusions 
This rehabilitation programme had no long-term benefits on the impact of multiple 
sclerosis on quality of life, but there was some evidence of an effect on everyday 
memory problems and mood. 
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 Introduction 
Up to 70% of people with multiple sclerosis experience cognitive problems, 
which negatively impact on function and quality of life1. Cognitive rehabilitation is a 
structured set of therapeutic activities to retrain cognitive skills or to improve people’s 
ability to cope with cognitive deficits in daily life. However, the evidence for the 
effectiveness of cognitive rehabilitation is weak. Several systematic reviews have 
found some positive effects of cognitive rehabilitation in people with multiple 
sclerosis, but these are based on poor quality randomised controlled trials (RCTs) 
with several methodological shortcomings, with review authors suggesting the level 
of evidence is “low” 2–4. No trial has evaluated the cost-effectiveness of cognitive 
rehabilitation. Therefore, the reviews have concluded that more high-quality trials are 
needed before firm conclusions can be reached. 2–4 
 
Although there is some support for the effectiveness of computerised 
cognitive rehabilitation to retrain cognitive skills in people with multiple sclerosis,4  
these studies have rarely included any long-term follow-up to assess whether the 
observed benefits persisted or generalised to daily life. There is less evidence for 
cognitive rehabilitation to teach people skills to cope with the cognitive impairment 
and provide aids to enable them to compensate for the loss of cognitive abilities. The 
ReMIND trial5 (n=72) evaluated the effectiveness of two types of group memory 
rehabilitation programme in neurological patients with memory problems, many of 
whom had multiple sclerosis (n=39). The memory rehabilitation programmes 
focussed either on restitution strategies (e.g. drill and practice exercises and 
teaching people to break down memory tasks into constituent parts) or 
compensation strategies (e.g. using external memory aids). The data from the study 
 indicated the interventions were worthy of further evaluation. Carr et al.6 (n=48) 
combined the restitution and compensation strategies from the ReMIND trial and 
compared this with usual care for patients with multiple sclerosis. The results 
showed a beneficial effect on mood, favouring cognitive rehabilitation. 
 
Therefore, the present trial was designed to assess the clinical and cost-
effectiveness of this cognitive rehabilitation programme for people with multiple 
sclerosis.  
 
This paper reports the main outcomes with further details available 
elsewhere.7 
 
Methods 
This was a pragmatic, multi-centre, observer-blinded randomised controlled 
trial comparing a cognitive rehabilitation programme (intervention) in addition to 
usual care, with usual care alone (control). The trial was conducted in five sites in 
England. Participants were identified through United Kingdom National Health 
Service hospitals, charities (e.g. MS Society) and the United Kingdom MS Register. 
Ethical approval was granted by West Midlands, South Birmingham Committee (Ref. 
14/WM/1083), the protocol was published8 and the trial was prospectively registered 
(ISRCTN09697576/14/08/2014). This work was funded by the National Institute for 
Health Research Health Technology Assessment programme (project number 
12/190/05) 
 
 Participants were recruited between 13 March 2015 and 23 March 2017. 
People with multiple sclerosis were eligible if they were: 
• aged 18 to 69 years  
• diagnosed with relapsing remitting or progressive multiple sclerosis  
• diagnosed at least 3 months prior to the screening assessment  
• reported having cognitive problems defined as >27 on the patient version of 
the Multiple Sclerosis Neuropsychological Screening Questionnaire9  
• impaired on at least one of the Brief Repeatable Battery of 
Neuropsychological tests,10 defined as performance >1 standard deviation 
(SD) below the mean of healthy controls, corrected for age and education11  
• able to attend group sessions 
• able to speak English sufficiently to complete the cognitive assessments, and  
• gave written informed consent. 
 
Potential participants were excluded if they:  
• had vision or hearing problems, such that they were unable to complete the 
cognitive assessments  
• had concurrent severe medical or psychiatric conditions, which prevented 
them from engaging in treatment 
• were involved in other psychological intervention trials. 
 
Demographic and clinical information were recorded.  
 
The Brief Repeatable Battery of Neuropsychological tests10 and Multiple 
Sclerosis Neuropsychological Screening Questionnaire9 were administered by an 
 Assistant Psychologist to check that participants met the inclusion criteria. The postal 
version of the Guy’s Neurological Disability Scale12 was administered to record the 
level of disability.  
 
Eligible participants were then given the following questionnaires to complete in 
their own time: 
• Multiple Sclerosis Impact scale13 version 2, to assess the impact of multiple 
sclerosis on quality of life  
• General Health Questionnaire 30 14, to detect psychological distress 
• Everyday Memory Questionnaire - participant version15, to assesses the 
frequency of cognitive problems in daily life  
• Fatigue Severity Scale16 5-item Rasch-analysed version, to assess fatigue. 
 
Participants were asked to nominate a relative or friend to complete the Everyday 
Memory Questionnaire - relative version.15  
 
At a subsequent visit, the Assistant Psychologist administered the following 
assessments: 
• Doors and People,17 an objective measure of memory function  
• Trail Making Test,18 to assess attention and executive abilities  
• European Quality of Life five-level version (EQ-5D-5L),19 a generic health-
related quality of life measure to calculate Quality Adjusted Life Year scores 
(QALYs) 
• Use of Health and Social Services questionnaire to assess healthcare 
utilisation and services provided by charities. 
  
The Assistant Psychologist checked participants’ availability to attend groups, 
should they be randomised to receive the intervention, and checked their preference 
to receive the outcome questionnaires by post or online. 
 
Groups of nine to eleven participants who could potentially attend for 
treatment at the same time and venue were individually randomised to either 
intervention or usual care on a 6:5 ratio. Allocation was stratified by recruitment site 
and minimised by multiple sclerosis type (relapsing remitting or progressive) and 
gender. The allocation algorithm was held on a secure server and the Assistant 
Psychologists at each site used a remote, internet-based randomisation system to 
obtain treatment allocations for each participant. Assistant Psychologists and 
participants were aware of the group allocation. 
 
Usual care comprised general advice from multiple sclerosis nurse specialists 
and occupational therapists on how to manage any cognitive difficulties. All 
participants were notified of information available on the webpages of multiple 
sclerosis charities, which include suggestions for coping with cognitive problems. All 
other clinical services, and support from specialist charities, were available as part of 
usual care. The usual care that participants received was recorded on the Use of 
Health and Social Services questionnaire. 
 
Cognitive rehabilitation was provided by an Assistant Psychologist to groups 
of four to six participants, who met approximately weekly for 10 sessions. The 
content of sessions was defined in a treatment manual, which was developed in a 
 previous study.6 The intervention included restitution strategies to retrain attention 
and memory functions, and strategies to improve encoding and retrieval. 
Compensation strategies taught included the use of internal mnemonics (such as 
chunking) and external devices (such as diaries and mobile phones), and ways of 
coping with attention and memory problems. Attendance was recorded. If 
participants missed a session, they could attend early for the following session to 
catch up on the content they had missed. Homework assignments facilitated 
individualisation of care and generalisation of cognitive strategies to daily life. 
 
Outcomes assessed at six and twelve months after randomisation included 
the Multiple Sclerosis Impact Scale, Everyday Memory Questionnaire - participant 
version, General Health Questionnaire 30, Fatigue Severity Scale, Brief Repeatable 
Battery of Neuropsychological tests, Doors and People, Trail Making, EQ-5D-5L, 
Use of Health and Social Services questionnaire and employment status. The Guys 
Neurological Disability Scale and number of relapses in the previous six months 
were also recorded. In addition, the participants’ nominated relative or friend 
completed the Everyday Memory Questionnaire - relative version and Modified Carer 
Strain Index20. 
 
Questionnaires were returned by post or completed online. Research 
Assistants, blind to treatment allocation, conducted outcome visits to complete 
cognitive tests and the Use of Health and Social Services questionnaire.  
 
The Multiple Sclerosis Impact Scale Psychological subscale at the 12-month 
follow-up was the primary outcome. A difference of 3-3.5 points on the Multiple 
 Sclerosis Impact Scale Psychological subscale was considered clinically meaningful. 
Based on the Multiple Sclerosis Impact Scale Psychological subscale, 143 
participants per group were required to detect a difference of 3 points, assuming a 
SD of 9, with 80% power and 5% two-sided alpha. However, a clustering effect may 
be expected to occur in the intervention arm due to the intervention being delivered 
in groups. Based on an average treatment group size of five evaluable participants 
and an inter-cluster correlation of 0.1 in the intervention group, an optimal allocation 
ratio of 6:5 in favour of the intervention group, a total of 336 evaluable patients would 
provide 80% power to detect such a difference. A total of 400 participants were to be 
randomised (216 to intervention and 184 to usual care) to allow for non-collection of 
primary outcome data in 15% of participants. 
 
The planned analyses were summarised in the Statistical Analysis Plan and 
Health Economic Analysis, which were finalised prior to database lock and release of 
the treatment allocation codes for analysis. All analyses were conducted using 
Stata/SE 14.1/15.1. 
 
The analysis was a modified intention-to-treat, i.e. analysis according to 
randomised group regardless of adherence to allocation and including only 
participants who provided outcome data at follow-up. The difference in mean 
outcome scores between the two groups at each time point were estimated using a 
multi-level linear model with site, multiple sclerosis type, gender and baseline score 
as covariates. Individuals allocated to usual care had no contact with each other and 
outcomes in this group were therefore assumed to be independent. However, 
participants allocated to cognitive rehabilitation received sessions together in groups. 
 Therefore, a fully heteroscedastic model estimated group-level residual variance in 
the intervention group, and also permitted individual-level residual variance to differ 
between groups. Assumptions for the multi-level linear model were checked using 
diagnostic plots. Missing baseline scores were imputed for the analysis using the 
mean score at each site.  
 
The primary health economic outcome consisted of a cost-utility analysis at 
12-months. Utility was estimated from EQ-5D-5L responses crosswalked to the 3L 
value set for England consistent with the guidance from the National Institute for 
Health and Care Excellence .21 Cost-utility and cost-effectiveness analyses were 
undertaken to estimate the incremental cost per QALY gained and incrementally cost 
per improvement in Multiple Sclerosis Impact Scale Psychological subscale score 
based on the primary clinical endpoint. Results of the comparative analysis of 
incremental costs and effects were summarised as incremental cost-effectiveness 
ratios.   
 
The study was overseen by an independent Trial Steering Committee and 
Data Monitoring Committee.  
 
Results 
Of the 449 participants randomised, 245 were allocated to cognitive 
rehabilitation and 204 to usual care (See CONSORT diagram, Figure 1). 
 
[Figure 1 about here] 
 
 The groups appeared well-matched on baseline characteristics (Table 1) and 
on baseline scores on questionnaire measures and cognitive tests (Table 2).  
 
[Table 1 about here] 
 
[Table 2 about here] 
 
Of the 245 allocated to cognitive rehabilitation, 208 (85%) attended at least 3 
sessions, the minimum number considered likely to effect a change. The mean 
attendance was 7.7 sessions (SD 3.5, range 0-10). Based on the Use of Health and 
Social Services questionnaire and feedback interviews, participants in the usual care 
group received no cognitive rehabilitation.  
 
Of the 449 participants, 214 (87%) in the intervention group and 173 (85%) in 
the control group were included in the primary analysis (See Figure 1). 
 
There was no evidence of any clinically important difference between the 
groups on the primary outcome, the Multiple Sclerosis Impact Scale Psychological 
subscale at 12 months (Table 3). Analysis of secondary outcomes showed there was 
evidence of a small difference on the Multiple Sclerosis Impact Scale Psychological 
subscale at 6 months favouring cognitive rehabilitation. Differences favouring 
cognitive rehabilitation were also found on the Everyday Memory Questionnaire 
participant and relative versions, and the General health Questionnaire 30, at both 
six and twelve months (Table 3). There were no differences on the Multiple Sclerosis 
Impact Scale Physical subscale, cognitive tests, fatigue, or Modified Carer Strain 
 Index. Employment status was no different between the groups. The level of 
disability on the Guys Neurological Disability Scale and number of relapses were 
similar in the two groups, indicating that results were not due to changes in the 
physical progression of multiple sclerosis.  
 
[Table 3 about here] 
 
No safety concerns were raised and no deaths reported.  
 
The cost of delivering the cognitive rehabilitation was estimated at £209 per 
participant, with 77% of the total cost attributable to the Assistant Psychologist 
delivering sessions. Mean total costs associated with cognitive rehabilitation of 
£5,885 (n=208) were over £800 lower than those of usual care £6,574 (n=170), but 
there was no evidence of a difference (p=0.27). Despite small QALY gains at 12-
months for both groups, there was no evidence of a difference between groups 
(p=0.2). The use of multiple imputation to address missing data for both costs and 
outcomes produced similar results with no evidence of a cost or QALY difference 
between groups (see Table 4). 
 
[Table 4 about here] 
 
Lower scores on the Multiple Sclerosis Impact Scale Psychological subscale 
represent less psychological impact of multiple sclerosis on quality of life therefore 
negative incremental differences favour the intervention. Positive incremental QALY 
differences favour the intervention. 
  
The cost-effectiveness plane for the EQ-5D (Figure 2) shows a distribution of 
estimates centred in the bottom right hand quadrant consistent with cognitive 
rehabilitation dominating usual care.  
 
[Figure 2 about here] 
 
The cost-effectiveness acceptability curve (Figure 3) shows a high probability 
of the intervention being cost-effective at willingness-to-pay thresholds between £0-
100,000. At a willingness-to-pay threshold of £30,000 per QALY gained, cognitive 
rehabilitation has a 97% probability of being cost-effective. 
 
[Figure 3 about here] 
 
Discussion 
 
This cognitive rehabilitation programme provided in addition to usual care did 
not reduce the psychological impact of multiple sclerosis on quality of life at 12 
months compared to usual care alone, but there was a small reduction in the 
psychological impact of multiple sclerosis at 6 months. Thus, there was some 
evidence to suggest that cognitive rehabilitation improved quality of life in the short-
term, but the effects were not maintained over time. There were differences between 
groups in the frequency of subjective complaints of cognitive problems from both 
people with multiple sclerosis and their relatives, and mood at both the 6 and 12-
month follow-ups favouring the cognitive rehabilitation group. 
  
Strengths of the study included a large sample size (with previous studies of 
cognitive rehabilitation having a mean of 42 participants2), and good attendance at 
sessions, so most people received most of the intervention. The attendance rate was 
consistent with the pilot study6, however, many studies do not report attendance 
rates22so direct comparisons of attendance rates across trials are limited. The 
reasons for non-attendance reflect aspects of daily life unrelated to cognitive 
problems, such as illness and holidays, rather than not wanting to continue in the 
group.  
 
There are, however, some limitations to the study. The lack of information on 
demographic characteristics of those who did not wish to take part limits the ability to 
determine the proportion of people who would be eligible for the treatment if it were 
routinely available. As a pragmatic trial, the inclusion criteria were intentionally broad 
to involve all those who might be treated in clinical practice, thereby increasing 
generalisability of the findings. However, almost half of those excluded was due to 
scoring too low on the Multiple Sclerosis Neuropsychological Screening 
Questionnaire, yet they believed they had cognitive difficulties. In the pilot study,6 
participants were recruited if they reported cognitive problems in daily life and no 
standardised assessment was used. The Multiple Sclerosis Neuropsychological 
Screening Questionnaire was used to provide a more replicable criterion. However, 
the cut-off of >27 was based on the original validation study11 and lower cut-offs 
have been recommended subsequently.23-25  Therefore, the sample included those 
with relatively severe cognitive problems in daily life, and these people may benefit 
less from the intervention.26  
  
The primary outcome was the Multiple Sclerosis Impact Scale Psychological 
subscale, which was developed specifically for people with multiple sclerosis, and 
includes items on mood, coping and cognition, has good psychometric properties 
and has been shown to be sensitive to the effects of rehabilitation. However, even on 
the Psychological subscale, some items are unlikely to be directly influenced by 
cognitive rehabilitation (such as “feeling unwell” or “problems sleeping”). Impact of 
multiple sclerosis and quality of life are multi-domain constructs and changing the 
impact of multiple sclerosis on quality of life, although desirable, may be unrealistic 
for interventions that focus on specific symptoms of multiple sclerosis. The research 
funder’s commissioning brief indicated that quality of life in the longer term was an 
important outcome, and therefore the Multiple Sclerosis Impact Scale Psychological 
subscale at 12-month follow-up was used.  
 
These findings are consistent with previous cognitive rehabilitation research in 
people with multiple sclerosis,27,28 in that they show benefits of cognitive 
rehabilitation that focusses on teaching strategies to cope with cognitive impairments 
in daily life on measures of memory problems in daily life. However, comparison with 
the ReMemBrIn trial,26 which evaluated the same intervention in people with 
traumatic brain injury, suggested that those with multiple sclerosis responded better 
than those with traumatic brain injury. One possible reason is that usual care for 
people with traumatic brain injury in the United Kingdom often includes cognitive 
rehabilitation whereas it does not for people with multiple sclerosis.  
 
 The finding of a beneficial effect on mood supports our pilot trial6 and the 
multiple sclerosis sub-group analysis of that trial,29 both of which used a similar 
treatment approach, and with a previous study of group treatment.27 A strong 
relationship has previously been documented30 between subjective cognitive 
problems and mood in people with multiple sclerosis. The beneficial effect on mood 
could therefore be partly attributable to the social contact afforded by attending 
sessions rather than the content of the intervention. However, it seems more likely 
that the change in mood was in response to changes in everyday memory because 
relatives’ reports of the frequency of everyday memory problems also showed a 
difference between groups, favouring the intervention group.  
 
The results indicated the intervention had no effect on cognitive impairment, 
as assessed on cognitive tests. In most studies which show changes in cognitive 
function the intervention comprises direct retraining of cognitive skills. The focus of 
the intervention in the CRAMMS trial was on learning to cope with cognitive 
problems and therefore, cognitive abilities would not necessarily be expected to 
change. There was also no evidence to suggest that the intervention exacerbated 
fatigue-related problems, which is positive and consistent with previous trials of 
cognitive rehabilitation.2  
 
Clinical Messages  
• We found no long-term effect of this cognitive rehabilitation programme on the 
impact of multiple sclerosis on quality of life 
• Cognitive rehabilitation improved memory problems in daily life and mood. 
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 Table 1. Baseline Characteristics of Participants 
 
Demographic and Clinical Characteristics 
Cognitive 
Rehabilitation 
n = 245 
Usual Care 
n = 204 
 Mean SD Mean SD 
Age 49.9 9.8 48.9 10.0 
Years of education 14.2 3.4 13.9 2.9 
Years since diagnosis 12.1 8.0 11.1 8.7 
 n % n % 
Gender Men 67 27 56 27 Women 178 73 148 73 
Ethnicity White 337 97 195 96 Non-white 8 3 9 4 
Marital status Single/divorced/widowed 81 33 66 32 Married/ with partner 164 67 138 68 
Living arrangements Alone 49 20 38 19 With others 196 80 166 81 
Employment status Not employed 163 67 134 65 Employed or in education 82 33 69 34 
Type of multiple 
sclerosis 
Relapsing remitting 159 65 132 65 
Primary progressive 22 9 24 12 
Secondary progressive 64 26 48 24 
 
 
  
 Table 2. Baseline Scores on Questionnaires and Cognitive Tests 
 
Measure 
Cognitive 
Rehabilitation Usual Care 
n Mean SD n Mean SD 
Multiple Sclerosis Neuropsychological 
Questionnaire 245 38.9 7.1 204 39.0 7.4 
Multiple 
Sclerosis Impact 
Scale 
Psychological 233 23.3 5.8 197 24.7 6.0 
Physical 232 52.0 13.6 197 53.4 13.1 
General Health Questionaire-30 230 36.5 14.2 197 39.7 15.8 
Everyday 
Memory 
Questionnaire 
Participant 229 45.0 22.8 194 47.1 23.2 
Relative 213 34.7 23.4 185 38.2 25.9 
Fatigue Severity Scale 230 1.4 1.4 197 1.3 1.3 
Guys Neurological Disability Scale 245 19.9 7.1 204 20.0 6.7 
EQ-5D-5L Visual Analogue 245 59.9 21.2 203 59.6 20.3 
Brief 
Repeatable 
Battery 
Selective Reminding 
Total  245 40.6 11.0 204 40.2 10.5 
Selective Reminding 
Delay 245 5.8 2.8 204 5.7 2.8 
10/36 Spatial Recall 
Total 245 18.1 4.5 204 18.3 4.9 
10/36 Spatial Recall 
Delay 245 6.0 2.2 204 6.3 2.1 
Symbol Digit 244 36.3 11.5 204 37.8 12.1 
PASAT - Easy 239 31.6 16.2 199 31.3 16.4 
PASAT - Hard 239 17.3 16.5 199 15.9 15.8 
Word Fluency 244 24.8 8.8 203 25.1 8.9 
Doors and 
People 
Overall Age Scaled 
Score 245 7.0 3.7 203 7.0 3.9 
Trail making B – A 244 71.7 41.0 200 69.6 41.4 
 
 
  
 Table 3. Comparison of Primary and Secondary Outcomes at 6 and 12-month follow-up 
 
 Time 
point 
(months) 
Cognitive Rehabilitation Usual Care Adjusted Difference 
n Mean SD n Mean SD Mean 95% CI p-value 
Primary Outcome           
MSIS-Psychological 12 214 22.2 6.1 173 23.4 6.0 -0.6 -1.5, 0.3 0.20 
Secondary Outcomes 
          
 
MSIS-Psychological 6 217 22.3 6.2 187 24.1 5.9 -0.9 -1.7, -0.1 0.03 
MSIS-Physical  6 215 51.4 13.3 187 53.0 3.9 -0.6 -2.2, 0.9  12 214 51.8 14.0 173 52.5 13.6 -0.1 -1.8, 1.5  
Everyday Memory 
Questionnaire-
participant  
6 214 37.6 23.4 181 44.5 23.5 -5.3 -8.7, -1.9  
12 210 37.9 22.9 168 43.1 24.0 -4.4 -7.8, -0.9  
Everyday Memory 
Questionnaire-
relative 
6 184 31.3 22.9 152 38.6 25.7 -5.4 -9.1, -1.7  
12 164 30.5 23.3 142 38.5 26.4 -5.5 -9.6, -1.5  
General Health 
Questionnaire-30 
6 212 32.9 15.1 183 37.8 14.8 -3.4 -5.9, -0.8  
12 209 33.9 16.1 167 38.3 16.2 -3.4 -6.2, -0.6  
Fatigue Severity Scale 6 214 1.1 1.4 185 1.1 1.4 -0.1 -0.3, 0.2  12 210 1.0 1.4 168 1.2 1.4 -0.3 -0.5, 0.0  
EQ-5D Visual 
Analogue 
6 224 61.7 19.5 187 59.9 20.2 2.6 -0.9, 6.0  
12 209 61.6 19.3 173 59.7 20.0 2.6 -0.9, 6.0  
Brief Repeatable 
Battery          
 
Selective reminding 
Total  
6 220 45.6 10.5 182 43.5 10.4 1.6 0.1, 3.0  
12 206 47.5 10.9 170 46.5 11.3 0.6 -0.9, 2.1  
Selective reminding 
Delay 6 220 6.7 2.9 182 6.5 2.9 0.2 -0.2, 0.6 
 
  12 206 7.5 2.8 170 7.1 2.9 0.4 0.1, 0.8  
10/36 Total 6 217 19.1 5.3 182 19.8 5.4 -0.6 -1.5, 0.3  
 12 206 20.1 4.9 170 20.4 5.4 -0.1 -1.0, 0.8  
10/36 Delay 6 217 6.6 2.3 182 6.6 2.3 0.0 -0.4, 0.4  
 12 206 6.8 2.2 170 7.0 2.3 -0.1 -0.5, 0.2  
Symbol Digit 6 220 41.4 12.1 181 40.7 12.7 1.3 -0.6, 3.2  
 12 205 39.9 11.9 170 39.9 12.8 0.4 -1.7, 2.5  
Paced serial addition 
Easy 6 217 36.6 16.1 178 35.7 17.6 0.0 -2.4, 2.5 
 
 12 205 36.4 17.8 169 36.5 17.7 -0.6 -3.1, 1.9  
Paced serial addition 
Hard 6 217 20.7 17.5 178 19.3 17.7 -0.3 -2.9, 2.2 
 
 12 205 18.5 19.2 169 19.2 18.9 -1.9 -4.8, 1.0  
Word Fluency 6 219 27.4 9.4 182 27.2 9.3 0.0 -1.3, 1.3  
 12 206 28.0 10.3 169 28.3 10.2 -0.2 -1.5, 1.2  
Doors and People 
(Overall Age Scaled 
Score) 
6 221 9.5 4.2 181 9.1 4.4 0.4 -0.1, 0.9  
12 206 10.5 4.1 168 9.9 4.4 0.6 0.0, 1.1  
Trail Making (B – A) 6 218 63.0 39.1 179 62.3 38.3 -0.3 -6.8, 6.2  12 205 61.3 39.7 165 63.0 40.3 -3.2 -10.0, 3.6  
Carer Strain Index 6 173 5.9 5.6 154 6.8 6.2 -0.9  -2.2, 0.4  12 159 5.8 5.2 141 6.2 6.0 -0.4 -1.6, 0.8  
    %   % Odds ratio 95% CI 
 
Any employment 6  62/224 28%  57/187 30% 0.88 0.55, 1.39  
 12  60/209 29%  50/173 29% 0.99 0.60, 1.63  
 
 
 Table 4. Cost and Quality Adjusted Life Year outcomes at 12-month follow-up 
 
 Usual Care 
n = 170 
 
Cognitive 
Rehabilitation 
n = 208 
Adjusted Difference 
Cost 
Effectiveness 
Plane 
Mean SD Mean SD Mean 95% CI  
Costs 6574  9188 5885 5641 -808 -2248, 632  
EQ-5D Quality 
adjusted life 
years 
0.57 0.27 0.60 0.25 0.01 -0.03, 0.05 
SE quadrant 
Intervention 
dominant 
MS Impact 
Scale 
Psychological  
23.4 6.0 22.2 6.1 -0.6 -1.5, 0.3 
SE quadrant 
Intervention 
dominant 
  
 Figure 1. Participant Flow 
  
6 month follow-up  
 
Primary outcome data n = 187(92%)   
 
6 month follow-up  
 
Primary outcome data n = 217 (86%)   
 
Randomised n = 449 
 (45 groups) 
ENROLLMENT  
RANDOMISATION 
Invited n = 3556 
2517 = postal invitation 
 561 = face to face invitation 
 198 = self-referral 
    45 = unspecified 
 235 = UK MS Register 
 
Consented n = 579 
NOT RANDOMISED n = 130 
   68 = not eligible 
   40 = recruitment closed 
   11 = withdrew consent 
     8 = lost to follow-up 
     3 = not known 
    
EXCLUDED n = 239 
   194 = not eligible 
     27 = declined to participate 
       9 = recruitment closed 
       2 = deceased 
       7 = other  
Initial Screening n = 818 
No response = 2738 
 
Usual care n = 204 
 
12 month follow-up  
 
Primary outcome data n = 173 (85%)   
            
 
Reason for no primary outcome data 
withdrew consent n = 16 
lost to follow-up n = 10 
returned questionnaire more than 15 months post 
randomisation n = 3 
visit completed, questionnaire not done n = 2 
 
FOLLOW-UP 
12 month follow-up  
 
Primary outcome data n = 214 (87%)  
            
 
Reason for no primary outcome data 
withdrew consent n = 13 
lost to follow-up n = 12 
returned questionnaire more than 15 months post 
randomisation n = 1 
visit completed, questionnaire not done n = 3 
MSIS-Psy not scoreable n = 1 
Not known n = 1 
 
Cognitive rehabilitation n = 245 
Attended at least one session  
n = 218 
 Figure 2. Cost-effectiveness Plane for EQ-5D-5L QALYs at 12-Months 
 
.  
 
 
  
 Figure 3: Cost-effectiveness Acceptability Curve for EQ-5D-5L QALYs at 12-Months 
 
 
